Biomedical Engineering Reference
In-Depth Information
[39] Yew NS, Wang KX, Przybylska M, Bagley RG, Stedman M, Marshall J, et al.
Contribution of plasmid DNA to inflammation in the lung after administration of cationic
lipid: pDNA complexes. Hum Gene Ther 1999;10:223-34.
[40] Yew NS, Zhao H, Przybylska M, Wu IH, Tousignant JD, Scheule RK, et al. CpG safety
and long-term gene expression in vivo . Mol Ther 2002;5:731-38.
[41] Yew NS, Zhao H, Wu IH, Song A, Tousignant JD, Przybylska M, et al. Reduced inflam-
matory response to plasmid DNA vectors by elimination and inhibition of immunostimu-
latory CpG motifs. Mol Ther 2000;1:255-62.
[42] Rettig GR, Rice KG. Non-viral gene delivery: from the needle to the nucleus. Expert
Opin Biol Ther 2007;7:799-808.
[43] Wiethoff CM, Middaugh CR. Barriers to nonviral gene delivery. J Pharm Sci
2003;92:203-17.
[44] Bally MB, Harvie P, Wong FMP, Kong S, Wasan EK, Reimer DL. Biological barriers to
cellular delivery of lipid-based DNA carriers. Adv Drug Delivery Rev 1999;38:291-315.
[45] Kamiya H, Tsuchiya H, Yamazaki J, Harashima H. Intracellular trafficking and transgene
expression of viral and non-viral gene vectors. Adv Drug Delivery Rev 2001;52:153-64.
[46] Sullivan SM. Introduction to gene therapy and guidelines to pharmaceutical develop-
ment. In: Rolland A, Sullivan SM, editors. Pharmaceutical gene delivery systems. 1st ed.
New York, NY: Marcel Dekker; 2003. p. 1-16.
[47] Chancham P, Hughes JA. Relationship between plasmid DNA topological forms and in
vitro transfection. J Liposome Res 2001;11:139-52.
[48] Vasir JK, Labhasetwar V. Polymeric nanoparticles for gene delivery. Expert Opin Drug
Delivery 2006;3:325-44.
[49] Byk G, Scherman D. Novel cationic lipids for gene delivery and gene therapy. Expert
Opin Ther Pat 1998;8:1125-41.
[50] Mumper RJ, Wang J, Klakamp SL, Nitta H, Anwer K, Tagliaferri F, et al. Protective
interactive noncondensing (PINC) polymers for enhanced plasmid distribution and
expression in rat skeletal muscle. J Control Release 1998;52:191-203.
[51] Walsh G. Nucleic-acid and cell-based therapeutics. In: Walsh G, editor. Pharmaceutical
biotechnology: concepts and applications. New Jersey: John Wiley & Sons; 2007.
p. 419-64.
[52] Hilla IRC, Garnetta MC, Bignottib F, Davisa SS. Determination of protection from serum
nuclease activity by DNA-Polyelectrolyte complexes using an electrophoretic method.
Anal Biochem 2001;291:62-8.
[53] Delphine LD, Verkman AS, Lukacs GL. Intracellular routing of plasmid DNA during
non-viral gene transfer. Adv Drug Delivery Rev 2005;57:755-67.
[54] Sigma Aldrich: Technical Bulletin—DEOXYRIBONUCLEASE I, Amplification Grade,
Product Code AMP-D1. http:// www.sigmaaldrich.com/etc/medialib/docs/Sigma/Bulletin/
ampd1bul.Par.0001.File.tmp/ampd1bul.pdf . [accessed on 03.02.10].
[55] Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA
delivery. Nat Rev Drug Discovery 2009;8:129-38.
[56] Hashida M, Mahato RI, Kawabata K, Miyao T, Nishikawa M, Takakura Y.
Pharmacokinetics and targeted delivery of proteins and genes. J Control Release 1996;41:
91-7.
[57] Konopka K, Fallah B, Monzon DJ, Overlid N, Duzgunes N. Serum-resistant gene
transfer to oral cancer cells by Metafectene and Gene Jammer: application to HSV-tk/
ganciclovir-mediated cytotoxicity. Cell Mol Biol Lett 2005;10:455-70.
[58] Nishikawaa MT, Takakuraa Y, Hashidab M. Theoretical considerations involving the
pharmacokinetics of plasmid DNA. Adv Drug Delivery Rev 2005;57:675-88.
Search WWH ::




Custom Search